Tohoku University Technology: Anti-Human LILRB4 Monoclonal Antibody：T20-3061
As a new immune checkpoint inhibitor, it is a treatment for cancer, autoimmune diseases, and Alzheimer's disease.
The present invention relates to a novel anti-human B4 monoclonal antibody that specifically binds to the human immune inhibitory receptor LILRB4 (leukocyte immunoglobulin-like receptor B4) and inhibits its binding to its physiological ligand, fibronectin (FN). Key points of the present invention: - Novel immune checkpoint inhibitor: The B4-FN pathway is involved in the expression of immune suppressive functions mediated by B4, so an immune checkpoint inhibitor with this antibody as an active ingredient provides a new option for cancer immunotherapy. - Broad applicability to various diseases: It is expected to be utilized as a therapeutic agent for a wide range of immune checkpoint-related diseases involving B4, such as cancer, autoimmune diseases, inflammatory diseases, allergic diseases, and Alzheimer's disease.
- Company：Tohoku Techno Arch Co., Ltd.
- Price：Other
